• 1. An antioxidative galactomannan extracted from Chinese Sesbania cannabina enhances immune activation of macrophage cells?
  Chongyang Zhu,Xiaojia Bian,Xin Jia,Ning Tang,Yongqiang Cheng Food Funct., 2020,11, 10635-10644
• 2. An alumina stabilized graphene oxide wrapped SnO2 hollow sphere LIB anode with improved lithium storage?
  Xiang Liu,Qian Sun,A. B. Djuri?i?,Maohai Xie,Baohu Dai,Jinyao Tang,Charles Surya,Changzhong Liao,Kaimin Shih RSC Adv., 2015,5, 100783-100789
• 3. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 4. An amino group functionalized metal–organic framework as a luminescent probe for highly selective sensing of Fe3+ ions?
  Zhonghua Xiang,Chuanqi Fang,Sanhua Leng,Dapeng Cao J. Mater. Chem. A, 2014,2, 7662-7665
• 5. An integrated chip for immunofluorescence and its application to analyze lysosomal storage disorders
  Jie Shen,Ying Zhou,Tu Lu,Junya Peng,Zhixiang Lin,Yuhong Pang,Li Yu Lab Chip, 2012,12, 317-324

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzothiazoles Benzothiazoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzothiazoles

Professional Introduction to 2-BROMO-5,7-DICHLOROBENZOTHIAZOLE (CAS No. 898747-71-2)

2-BROMO-5,7-DICHLOROBENZOTHIAZOLE, identified by the Chemical Abstracts Service Number (CAS No.) 898747-71-2, is a heterocyclic organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the benzothiazole family, a class of molecules widely recognized for their diverse biological activities and utility in drug development. The structural features of 2-BROMO-5,7-DICHLOROBENZOTHIAZOLE, particularly the presence of bromine and chlorine substituents on the benzothiazole core, contribute to its unique chemical reactivity and potential applications in synthetic chemistry and bioactivity studies.

The benzothiazole scaffold is a privileged structure in medicinal chemistry, exhibiting a broad spectrum of pharmacological properties. It serves as a key pharmacophore in numerous therapeutic agents, including those targeting infectious diseases, cancer, and neurological disorders. The introduction of halogen atoms, such as bromine and chlorine, into the benzothiazole ring system enhances its interactability with biological targets, making it a valuable intermediate in the synthesis of more complex molecules.

In recent years, 2-BROMO-5,7-DICHLOROBENZOTHIAZOLE has been explored as a versatile building block in the development of novel pharmaceuticals. Its halogenated structure allows for further functionalization through various chemical transformations, such as cross-coupling reactions, nucleophilic substitutions, and metal-catalyzed coupling reactions. These modifications enable the creation of derivatives with tailored biological activities, making it a promising candidate for drug discovery campaigns.

One of the most compelling aspects of 2-BROMO-5,7-DICHLOROBENZOTHIAZOLE is its potential application in the synthesis of small-molecule inhibitors targeting enzyme-catalyzed pathways. For instance, researchers have utilized this compound to develop inhibitors of kinases and other enzymes implicated in cancer progression. The bromine atom at the 2-position provides a handle for palladium-catalyzed cross-coupling reactions, allowing for the introduction of aryl or heteroaryl groups that can modulate enzyme binding affinity and selectivity.

Moreover, 2-BROMO-5,7-DICHLOROBENZOTHIAZOLE has been investigated in the context of antiviral and anti-inflammatory drug development. The structural motif is known to interact with viral proteases and inflammatory mediators, offering a rational basis for its incorporation into lead compounds. Preclinical studies have demonstrated that derivatives of benzothiazole exhibit inhibitory effects on enzymes such as HIV protease and cyclooxygenase-2 (COX-2), which are critical in viral replication and inflammation.

The synthesis of 2-BROMO-5,7-DICHLOROBENZOTHIAZOLE typically involves multi-step organic transformations starting from commercially available precursors. A common synthetic route includes chlorination followed by bromination of a substituted benzothiazole intermediate. The precise control over regioselectivity during these steps is crucial to obtaining the desired product with high yield and purity. Advanced synthetic methodologies, such as transition-metal-catalyzed reactions and flow chemistry techniques, have been employed to optimize the production process and enhance scalability.

Recent advancements in computational chemistry have further accelerated the discovery process involving 2-BROMO-5,7-DICHLOROBENZOTHIAZOLE. Molecular modeling studies have been conducted to predict binding interactions between this compound and biological targets, providing insights into its mechanism of action. These computational approaches complement experimental efforts by allowing researchers to screen large libraries of derivatives virtual before synthesizing them in the lab.

The pharmaceutical industry has shown particular interest in 2-BROMO-5,7-DICHLOROBENZOTHIAZOLE due to its potential as an intermediate in producing next-generation therapeutics. Companies specializing in custom synthesis have made this compound available for research purposes under strict quality control measures. The demand for high-purity 2-BROMO-5,7-DICHLOROBENZOTHIAZOLE reflects its importance as a key material in drug discovery pipelines.

In conclusion, 2-BROMO-5,7-DICHLOROBENZOTHIAZOLE (CAS No. 898747-71-2) represents a significant compound in modern pharmaceutical research. Its unique structural features and reactivity make it an invaluable tool for developing novel therapeutic agents targeting various diseases. As research continues to uncover new applications for this molecule, 2-BROMO-5,7-DICHLOROBENZOTHIAZOLE is poised to play an increasingly important role in the next wave of drug innovation.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)